Também conhecido como
HLA-B27 antigen
Nome formal
Human leukocyte antigen B27
Este artigo foi revisto pela última vez em
Este artigo foi modificado pela última vez em
21 de Junho de 2018.
At a Glance
Why Get Tested?
To determine whether you have human leukocyte antigen B27 (HLA-B27) on the surface of your cells; to help assess the likelihood that you have an autoimmune disorder associated with the presence of HLA-B27
When To Get Tested?
When you have symptoms of chronic inflammation, pain, and stiffness in certain areas of your body, such as your back, neck, and chest, or eyes, especially if you are male and the symptoms began in your early 30s
Sample Required?
A blood sample drawn from a vein in your arm
What is being tested?
This test detects the presence or absence of human leukocyte antigen B27 (HLA-B27) on the surface of white blood cells in a blood sample. Human leukocyte antigens (HLA) are a group of proteins that help the body’s immune system to identify its own cells and to distinguish between “self” and “nonself.” Everyone has an inherited combination of HLA antigens present on the surface of his or her white blood cells (leukocytes) and other nucleated (containing a nucleus) cells. These HLA antigens are divided into types: Class I (A, B, C) and Class II (DR, DP, DQ). While not as unique as a fingerprint, the presence or absence of each antigen creates a distinctive HLA combination for each person.

HLA-B27 is found in about 5-10% of the U.S. population. Its presence has been associated with several autoimmune disorders. The most common of these disorders is ankylosing spondylitis (AS). Approximately 90% of patients with AS are positive for HLA-B27. Other disorders that have an association with the presence of HLA-B27 include:

  • Juvenile rheumatoid arthritis (JRA), in which about 80% of affected patients are positive for HLA-B27.
  • Reiter’s syndrome (also known as reactive arthritis), with about 50-80% of patients are positive.
  • Isolated acute anterior uveitis, with about 40-70% of cases are positive.
  • HLA-B27 may also be present in patients with inflammatory bowel disease and with a range of other chronic conditions. While HLA-B27 has not been established as a cause of these disorders, there is a higher prevalence of this antigen in those affected.

    How is the sample collected for testing?

    A blood sample is obtained by inserting a needle into a vein in the arm.

    Is any test preparation needed to ensure the quality of the sample?

    No test preparation is needed.
    Accordion Title
    Common Questions
    • How is it used?
      The HLA-B27 test is primarily ordered to help strengthen or confirm a suspected diagnosis of ankylosing spondylitis (AS), Reiter’s syndrome (reactive arthritis), or sometimes anterior uveitis. The HLA-B27 test is not a definitive test that can be used to diagnose or rule out a disorder. It is used as one piece of evidence in a constellation of signs, symptoms, and lab tests to support or rule out the diagnosis of certain autoimmune disorders, such as AS and Reiter's syndrome. Both AS and Reiter’s syndrome are chronic progressive conditions that occur more frequently in men than women, and the first symptoms usually occur when a patient is in his early 30's. Ankylosing spondylitis is characterized by pain, inflammation, and a gradual stiffening of the spine, neck and chest. Reiter’s syndrome is a group of symptoms that includes inflammation of the joints, urethra, eyes, and skin lesions. Often, the initial symptoms of these autoimmune disorders are subtle and may take several years before characteristic degenerative changes to bones and joints are visible on X-rays. Anterior uveitis is associated with recurring inflammation of the structures of one or both eyes.

      The HLA-B27 test may be ordered as part of a group of tests used to diagnose and evaluate conditions causing arthritis-like chronic joint pain, stiffness, and inflammation. This group of tests may include an RF (rheumatoid factor) with either an ESR (erythrocyte sedimentation rate) or a CRP (C-Reactive protein). HLA-B27 is sometimes ordered to help evaluate someone with recurrent uveitis that is not caused by a recognizable disease process.

    • When is it ordered?
      An HLA-B27 test may be ordered when a patient has acute or chronic pain and inflammation in his spine, neck, chest, eyes, and/or joints, and the doctor suspects an autoimmune disorder that is associated with the presence of HLA-B27. Doctors frequently must rely on their clinical findings and the HLA-B27 test result when diagnosing ankylosing spondylitis, and other HLA-B27 related disorders, because the characteristic changes to the bones may not be detectible for several years. Under these circumstances, HLA-B27 is not diagnostic but adds additional information, increasing or decreasing the likelihood that the patient has ankylosing spondylitis. An HLA-B27 may also be ordered when a patient has recurrent uveitis.
    • What does the test result mean?
      HLA-B27 will be present or absent. If it is present, then the HLA-B27 antigen exists on the surface of the body’s white blood cells and other nucleated (containing a nucleus) cells. If a patient has HLA-B27 and has symptoms such as chronic pain, inflammation, and/ or degenerative changes to his bones (as seen on X-ray), then it supports a diagnosis of AS, Reiter’s syndrome, or another autoimmune disorder that is associated with the presence of HLA-B27. This is especially true if the patient is young, male, and if he experienced his first symptoms before the age of 40.

       

      If HLA-B27 is not present, then the association is not there. This does not, however, mean that the person does not have the suspected condition, as a certain percentage of patients with each disorder will be HLA-B27 negative.

      A positive HLA-B27 in a person who does not have symptoms or a family history of HLA-B27 associated disease is not clinically significant. It does not help predict the likelihood of developing an autoimmune disease. If a patient does have an associated disorder, the presence of HLA-B27 cannot be used to tell which disease is present, how quickly it will progress, its severity, prognosis, or the degree of organ involvement.

    • Is there anything else I should know?
      Whether or not HLA antigens will be present is genetically determined. Their production is controlled by genes that are passed from parents to children. If one of your family members has a HLA-B27 related disease that affects the joints of the spine (AS or other related condition) and you have the HLA-B27 antigen, then you have a higher risk of developing a similar disease.

      With new genetic testing methods, it is now possible to separate HLA-B27 into subtypes. So far, about fifteen different subtypes have been identified. The most common in the U.S. are HLA B27*05 and HLA B27*02. How the presence of these specific subtypes affects the likelihood of developing an autoimmune disease is not yet known.

    • What causes the autoimmune disorders?
      In most cases, the cause is not known. However, in some cases of Reiter’s syndrome, there is an association between a previous infection by a microorganism, such as Chlamydia, Campylobacter, Salmonella, Ureaplasma, or Yersinia, and the onset of the disease. It is thought that similarities between the HLA-B27 antigen and the antigens found on the surface of the microorganisms trigger the immune system to fight both the microorganism and the patient's own tissues, launching the autoimmune disorder after the resolution of the infection.
    View Sources
    S1
    Thomas, Clayton L., Editor (1997). Taber’s Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

    S2
    Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby’s Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

    S3
    Ankylosing spondylitis [10 paragraphs]. Hendrick Health System, AceessMed Online Health Information Library [On-line information]. Available FTP: http://www.ehendrick.org/healthy/

    S4
    HLA-B27 [5 paragraphs]. ARUP's Guide to Clinical Laboratory Testing (CLT) [On-line information]. Available FTP: http://www.aruplab.com/guides/clt/tests/clt_a287.htm#1195370

    S5
    Diagnosis, Symptoms, and Treatment [5 paragraphs]. Spondylitis Association of America [On-line information]. Available FTP: http://www.spondylitis.org/html/htmlpages.asp?load=diagnosis_what.htm

    S6
    Mayo Clinic Staff (2003 June 05). Ankylosing spondylitis [34 paragraphs]. MayoClinic.com, Diseases and Conditions [On-line information]. Available FTP: http://www.mayoclinic.com/invoke.cfm?id=DS00483

    S7
    Kovacs, B. (2001 November 29, Updated). Reiter’s syndrome [14 paragraphs]. MEDLINEplus Health Information, Medical Encyclopedia [On-line information]. Available FTP: http://www.nlm.nih.gov/medlineplus/ency/article/000440.htm

    S8
    Milone, M. (2001 November 19, Updated). Histocompatibility antigens [13 paragraphs]. MEDLINEplus Health Information, Medical Encyclopedia [On-line information]. Available FTP: http://www.nlm.nih.gov/medlineplus/ency/article/003550.htm

    S9
    Milone, M. (2001 December 5, Updated). HLA-B27 antigen [13 paragraphs]. MEDLINEplus Health Information, Medical Encyclopedia [On-line information]. Available FTP: http://www.nlm.nih.gov/medlineplus/ency/article/003551.htm

    S10
    (2003 May 21, Updated). Spondylitis: Frequently Asked Questions [16 paragraphs]. Spondylitis Association of America [On-line information]. Available FTP: http://www.spondylitis.org/about/faq.aspx

    S11
    (2003 June 19, Updated). Reactive Arthritis/Reiter's Syndrome (ReA), Diagnosis [16 paragraphs]. Spondylitis Association of America [On-line information]. Available FTP: http://www.spondylitis.org/about/reactive/diagnosis.aspx

    S12
    Agrawal, S. (2003 August 15). Immunophenotyping using flow cytometry [9 paragraphs]. Express Healthcare Management [On-line Newspaper, India]. Available FTP: http://www.expresshealthcaremgmt.com/labwatch/lab6.shtml

    S13
    Waheed, N. (1998). HLA-B27 Associated Uveitis [24 paragraphs]. Massachusetts Eye & Ear Infirmary, Ocular Immunology & Uveitis Service [On-line information]. Available FTP: http://www.uveitis.org/Enhanced/MD_info/md_hlab27.htm

    S14
    Pagana, Kathleen D. & Pagana, Timothy J. (© 2007). Mosby’s Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp. 544-545.

    S15
    (© 2007). Ankylosing Spondylitis (AS) Diagnosis [10 paragraphs]. Spondylitis Association of America [On-line information]. Accessed on: 9/09/07. Available FTP: http://www.spondylitis.org/about/as_diag.aspx

    S16
    Alexander, D. (2007 May 29, Updated). HLA-B27 antigen [15 paragraphs]. MedlinePlus Medical Encyclopedia [On-line information]. Accessed on: 9/09/07. Available FTP: http://www.nlm.nih.gov/medlineplus/ency/article/003551.htm

    S17
    Thjodleifsson, B. et. al.(2007 July 30). Evidence of a Common Genetic Background for Ankylosing Spondylitis and Inflammatory Bowel Disease [7 paragraphs]. American College of Rheumatology from Arthritis & Rheumatism 2007; (DOI:10.1002/art.22812). [On-line journal article]. Accessed on: 9/09/07. Available FTP: http://www.rheumatology.org/press/2007/0730ankylosing.asp

    S18
    (© 2007). Ankylosing Spondylitis [10 paragraphs]. American College of Rheumatology [On-line information]. Accessed on: 9/9/07. Available FTP: http://www.rheumatology.org/public/factsheets/as.asp?aud=pat

    S19
    Waheed, N. (© 1996-2006). HLA-B27 Associated Uveitis [25 paragraphs]. The Ocular Immunology and Uveitis Foundation [On-line information]. Accessed on: 9/09/07. Available FTP: http://www.uveitis.org/medical/articles/case/hlab27.html